European biotechs presented a range of interesting technologies and novel therapeutic biotechs at the recent BioTrinity conference, organized by BioUK, formerly OBN. The meeting highlighted a spectrum of cell and protein-based therapies, as well as novel delivery methods, with eye-catching investments and partnering opportunities.
One of the stand-out technologies discussed by U.K.-based University of Southampton spin-out Renovos Biologics was the use of synthetic nanoclays. However, these are not being used for their traditional application of controlling drug release, but rather, for medical delivery. According to Agnieszka Janeczek, PhD, “We are developing an injectable, biodegradable nanoclay for use with bone morphogenetic protein 2 (BMP-2), a crucial growth factor in bone regeneration. We intend to use this on patients who have had spinal fusions after trauma or sports injuries.”
Current treatments to encourage bone growth after spinal fusion, such as BMP-2 in its current formulations, are poorly retained around the spine, causing inflammation or, worse, bone growth outside the spine. This often leads to patients needing revision surgery at a cost of up to $50,000. “BMP-2 was used around fusions in the cervical spine, but the growth of bone and inflammation caused some patients to develop breathing difficulties and has resulted in a black box warning against using BMP-2 for this application,” noted Janeczek.
To overcome these issues, the company has developed a synthetic nanoclay that provides a localized environment conducive to cell infiltration. The nanoclay retains the BMP-2 bioactive molecule until newly regenerated tissue gradually replaces it.
“We have used RENOVITE® with BMP-2 so that this protein is injectable with a 23-gauge needle to deliver BMP-2 in a gel to allow precise templating of new bone formation, and therefore safer and more efficient bone fusion,” she continued. “Using our nanoclay, we see better quality bone growth as the bone grows evenly around and through the fusion, unlike BMP-2 on its own, which can sometimes initiate bone growth around the fusion to create an eggshell effect with bone only on the outside.”
Renovos Biologics, which is developing an injectable, biodegradable nanoclay for use with bone morphogenetic protein 2, intends to use this crucial growth factor in patients who have had spinal fusions after trauma or sports injuries. [Vadym Terelyuk/Getty Images]
The Renovos nanoclay retains the BMP-2 protein more readily around the fusion. As a result, it is possible to administer BMP-2 in a lower dosage, giving it the potential benefit of use in lower-cost markets, said Janeczek, and concluded that “Twenty-one percent of lumbar fusions are in patients that are younger than 45 years old, and the market for bone fusion could be worth $24.5 billion by 2035. Our lead asset RENOVITE BMP-2 will enter first-in-human trials by 2027, and we welcome investment to help assess this game-changing product in the clinic.”
Patching up wounds
Thomas Hafner, CEO of Onya Therapeutics, based in Ebbw Vale, U.K., stated that “For 25 years, wound care has been an innovation desert because therapies are difficult to scale and are not easy to adapt. This is not a glamorous area, but it is a massive opportunity.”
To address this issue, several companies are developing devices, artificial skin, or anti-microbials. Others are developing sponges for managing exuding wounds, making them thicker for better absorption. As Hafner pointed out, they are doing this without asking, “Is this the right approach? “Wound care is a massive problem. For example, 30% of patients with diabetic foot ulcers will lose a limb within five years. Globally, there are triple the number of patients with chronic wounds as there are with cancer—wound care is a $400 billion crisis in plain sight.”
Currently, with wound care, 90% of the costs are for the labor to manage the wound and only 6% for the products themselves. To address this, Onya says it is developing a treatment that could collapse the 90% costs of wound management by accelerating healing. The company calls it active exudate therapy.
“In chronic wounds, the amount of exudate increases, and so instead of mopping up the exudate with dressings, we have found a way of turning off the tap. By doing this, we encourage healing and reduce amputations, potentially saving billions of dollars,” Hafner noted.
Onya, which closed a £2.6 million seed financing round in 2025, is utilizing a compound known as OTX-PP01, based on potassium permanganate, a molecule with long-established clinical safety and broad antimicrobial and astringent action. This compound is delivered via a patch. “Unlike other wound management treatments, we don’t absorb the fluid; instead, our OTX-PP01 patch supports reduction of excessive exudate by addressing chronic inflammation, and creating the conditions for healing to restart,” said Hafner.
Onya Therapeutics’ OTX-PP01 patch supports reduction of excessive exudate by addressing chronic inflammation, and creating the conditions for healing to restart. [Victor Golmer/Getty Images]
The compound does this in two ways: first, it targets exudate with an astringent action that can reduce excessive wound fluid at the source, targeting the inflammatory cycle that can stall healing. Second, it addresses inflammation using a broad-spectrum antimicrobial action targeting pathogens through oxidation.
“OTX-PP01 is not a new molecule. It has over 150 years of safe clinical use, but the delivery method is new,” explained Hafner. “The patch is easy to fit, and a nurse can put it on the wound and leave it on for 15 minutes for the compound to absorb and do its job of healing. After removing the patch, a nurse can then redress the wound.”
Onya has designed its OTX-PP01 patch product to treat diabetic foot ulcers, venous leg ulcers, and pressure ulcers. It does not have to undertake Phase I studies as these were waived based on the established safety profile of the active compound. “We have a Phase II/III adaptive trial design, which we hope to complete in the next four to five years. Our aim with OTX-PP01 is to transform wound management to wound healing,” said Hafner.
Eyes on the prize
Therapies for treating ophthalmic diseases were also noteworthy at BioTrinity, with StemSight and Link Biologics presenting data on their promising clinical candidates. StemSight, based in Tampere, Finland, is a biotech company spun out from Tampere University. The firm is developing off-the-shelf induced pluripotent stem cell (iPSC) therapies to cure corneal blindness.
According to Laura Koivusalo, PhD, CEO and founder of StemSight, the market value of regenerative medicine products across a variety of indications was $63 billion in 2026. However, the bottleneck for making these therapies widely available is manufacturing and scaleup. Koivusalo said that “Recently in Japan, the first iPSC treatments have been approved for use, and the advantage of using iPSCs combined with biomaterials is that they provide efficient and durable therapies.”
Her company is developing a therapy to treat limbal stem cell deficiency (LSCD), a rare disease that causes blurry vision due to corneal epithelium loss and eventually blindness. There are over 240,000 sufferers worldwide, and there are currently no treatments for this condition available for most patients.
“The only treatment option for LSCD is available only to patients with one healthy eye,” Koivusalo explained. “Scientists can harvest limbal stem cells from the healthy eye and transplant them into the diseased one to restore the damaged surface cells. The therapy proves that the cell transplantation approach works, but this is a personalized autologous treatment. Additionally, if both eyes have LSCD, and the patient is truly blind, this treatment is not possible as there are no healthy stem cells available to harvest. That’s where the high value of cure is really measured.”
StemSight is developing an allogenic limbal stem cell therapy, which uses gene-edited iPSCs to reduce immunogenicity. Currently, the firm can produce one hundred patient doses per batch using a GMP-compliant process. It then freezes these cells until their delivery on a biomaterial carrier for patients.
StemSight and Link Biologics presented data in their talks on their promising clinical candidates for ophthalmic diseases. [Shironosov/Getty Images]
“Our process produces high-quality stem cells for a low cost of goods,” continued Koivusalo. “We are currently in late preclinical development with our lead product, STE-101, and have shown that we can regenerate corneal epithelium in rodent models using imaging and histology. These are objective measures of efficacy, as we cannot ask rodents if they can read a chart.”
StemSight is aiming to treat ten patients in a Phase I/II study starting early 2028.
Unlike StemSight, Link Biologics, a U.K.-based spin-out from the University of Manchester, is developing first-in-class biologics to treat Dry Eye Disease (DED) and Wet Age-related Macular Degeneration (AMD). The firm is developing therapies based on TSG-6 (Tumor Necrosis Factor-α-Stimulated Gene/Protein-6), a secreted glycoprotein that has an endogenous role to protect tissues from inflammatory damage and promote repair. Link’s TSG-6-based therapies have enhanced activities compared to the native protein and thus have a unique combination of anti-inflammatory, tissue-protective, and tissue-reparative properties.
Reuben Dawkins, CEO and co-founder of Link Biologics, stated that “We are using these protein biologics to treat DED and wet AMD because these are billion-dollar markets where there are limited treatment options available. Current standard of care for DED, for example, involves cyclosporine, which has a 15% response rate, or Xiidra, where 50% of pivotal trials did not show improvement in key efficacy measures vs no treatment. Overall, nine in ten DED patients stop using their initial medication within one year.”
The company’s lead candidate, LB001, is in preclinical development for the treatment of DED. Dawkins presented data to show that in mouse models, twice daily administration of LB001 for seven days reduced corneal epithelial damage and suppressed inflammatory markers compared to a branded cyclosporine (Restasis).
“Unlike other treatments, LB001 has a dual tissue-repair and anti-inflammatory action which may make this molecule more effective than current therapies,” noted Dawkins. “We have completed CMC so are able to manufacture LB001 to GMP standards, and it is stable as an eye drop formulation. We will be taking LB001 into a 180-patient Phase I/II clinical trial, which we aim to commence in 2027.”
Sue Pearson, PhD, is a freelance writer based in the U.K.
At the end of a tense and scoreless first half of a soccer match between the English men’s team and rival Germany, millions of Brits let out a collective sigh and did what they so often do in moments of stress: They made tea. That wave of electric kettles clicking on, however, caused a different kind of stress: a huge and sudden increase in demand for electricity. But National Grid, which operates the local transmission network, was ready.
Just as those kettles started heating up, an AI program sent instructions to a data center in London to slow down some of the facility’s power-hungry chips. This reduction helped make sure there was enough supply to match demand, staving off potential blackouts or damage to electrical hardware. For data centers, which normally guzzle power without consideration for anyone or anything else’s needs, it was a radical departure.
It was also a simulation. In December 2025, engineers sought to test a new breed of data center built to be flexible about its electricity needs, so they re-created the energy demand facing the UK’s grid during a match from the 2020 Euro tournament. They wanted to see how their software, called Conductor, would have responded had it been online at the time.
Conductor is the signature product of Emerald AI, a firm based in Washington, DC, that’s part of a wave of companies trying to figure out whether data centers can work within the confines of the existing electric grid.
This year, Emerald is set to deploy Conductor in a new facility in the part of Virginia known as Data Center Alley, this time connected to the live grid. When overall demand spikes, Conductor will turn down the power used by the data center, while making sure its servers still carry out their timeliest and most important jobs. Emerald’s partners on the project—which include Nvidia and the giant data-center operator Digital Realty—bill it as one of the world’s first “power-flexible AI factories.”
Demonstrating that data centers can participate in this kind of give-and-take could ease what many tech leaders identify as the bottleneck in getting facilities online: It takes far longer to get approval for, construct, and connect new power plants than to build data centers. PJM, the grid operator in Virginia and the largest one in the US, for instance, needs eight years to bring new generation online, according to RMI, an energy research and advocacy group. “We need to solve the energy equation,” says Josh Parker, head of sustainability at Nvidia. “AI factory flexibility is the bridge between the incredible demand for AI and the immediate limitations of our energy grid.”
Speed, though, is only one of the issues. Once facilities do plug in, neighbors often criticize them for drawing too much electricity and contributing to rising prices. They say the data centers generate more noise than they do long-term jobs, contribute to pollution, and threaten to put people out of work. Organizers stalled over $150 billion worth of projects in 2025, according to Data Center Watch, and policymakers alert to the public mood are starting to impose limitations on development.
More than a dozen states are considering bans, and local moratoriums are in effect in places like Minneapolis and DeKalb County in Georgia. At the federal level, the GRID Act, a bipartisan bill in the US Senate, proposes to sever new data centers from public grids entirely. Some operators are already moving that way by trying to develop their own power generation.
Rather than rushing to build new power plants, companies could find part of the solution to the crunch right under our noses—or, more precisely, in the transmission lines under our feet and above our heads. The existing system operates near its full capacity during only a small number of high-demand hours throughout the year. This means, some grid experts argue, that if data centers can limit the power they draw during those stretches, they won’t need to wait for big infrastructure upgrades or build their own off-grid generation.
Indeed, a growing number of studies have shown there could be plenty of power available for data centers that can flex. A widely discussed 2025 report from researchers at Duke University found that the US grid could offer an additional 76 gigawatts—about 5% of its entire capacity, and about enough to accommodate projected data-center growth in the US through 2030—to facilities that are willing to reduce their usage just 0.25% of the time. That’s about 22 hours a year. And when researchers from Princeton University and two grid-modernization companies looked at locations for new data centers in the PJM region, their report, which was funded by Google, found that a 500-megawatt facility capable of flexing for less than 1% of the year could reach full operation three to five years faster than one that’s inflexible.
Flexible power connections could also help data centers address some of their PR problems. By decreasing their draw at times of grid stress, for instance, they could avoid diverting power from where it’s most needed, thus boosting stability. By using existing capacity, they might be able to reduce the need for new fossil-fuel power plants and spread fixed costs over more electricity users, pushing prices down.
The AI power pinch is attracting resources and research into strategies for grid flexibility overall, which could help negotiate a tricky period: Taken together with electric vehicles, air-conditioning, and other sectors, data centers are helping drive what analysts predict will be a 25% increase in US electricity demand by 2030 compared with 2023 levels.
Ideally, flexibility gives grid operators more control over the flow of electrons, making them leaders of a harmonious ensemble rather than hostages to inflexible electricity requirements. That will help them manage demand spikes across the entire system and deal more effectively with the intermittent nature of renewables like wind and solar. “Demand flexibility is incredibly useful for power grids,” says Johanna Mathieu, a grid expert at the University of Michigan. “It helps reduce electricity costs and improve grid reliability.”
But while advocates see plenty of benefits, the concept brings complexity. For data centers, compromising on energy needs can be a hard sell. Flexibility requires utilities and grid operators, which tend to be operationally conservative, to change long-held practices. And some skeptics also say that flexibility distracts from the very real need to build more grid infrastructure faster, and could even pose risks to our electricity supply.
Still, some technologists, grid operators, and utilities are hoping to show that flexibility works—not only in white papers or simulations but in real life.
The poster children for data-center growth default toward inflexibility. Hyperscalers like Microsoft and Oracle have proposed enormous new centers, many of which would rely on off-grid, natural-gas-burning power plants. When xAI wanted to speed up the buildout of the Colossus site outside Memphis, Tennessee, it rolled up with gas turbines on flatbed trucks. The facility, now in operation, is facing blowback from regulators and residents about the spike it’s causing in emissions and other pollution. In any case, there aren’t enough gas turbines worldwide to meet the demand from data-center operators.
One big obstacle for anyone demanding a lot of power is that our grids are mostly rigid. They’re designed to supply enough power to meet total demand when it’s highest, even if that’s for only a relatively small number of hours a year. That conservative approach is a simple route to reliability, but it means that the grid has quite a bit of headroom. “The grid is already overbuilt by a lot. If you were an airline running at 30% utilization, you would not buy more planes,” says Amit Narayan, the cofounder and CEO of GridCare, a company developing flexibility technologies, referring to a 2025 Stanford study of transmission lines in western North America. “If you are running a grid at 30% utilization, there’s no scientific reason you can’t go to 60.”
“If you were an airline running at 30% utilization, you would not buy more planes. If you are running a grid at 30% utilization, there’s no scientific reason you can’t go to 60.”
To be fair, the idea of flexibility isn’t entirely foreign to grid operators. For decades, they’ve practiced a technique called demand response: When it looks as if demand will get too close to supply, as it might during a heat wave when many people turn on the AC at the same time, they call large commercial or industrial facilities and ask them to shut down parts of their operations. This method can help avoid the need to fire up so-called peaker plants, which run on fossil fuels, but it’s slow, imprecise, and hard to scale.
In the 2000s, as the adoption of technologies like electric cars and solar panels presented new challenges, more internet-connected grids also provided new means of flexibility. Virtual power plants, or VPPs, offered a smarter, faster, more granular alternative. Electricity customers ranging from factories to homeowners with smart thermostats, solar panels, or big batteries would allow the utility to adjust their draw to help meet demand—often getting paid for their (frequently unnoticed) trouble.
After the generative AI boom began with the release of ChatGPT in 2022, some companies began to see flexibility as a way to get data centers set up more easily, efficiently, and affordably. If they bring AI money into existing grids and reduce or defer the need for expensive upgrades, data centers could actually help spread out fixed costs so as to lower rates for other users. A study from Duke University published this past February, for instance, found that flexibility could reduce rates by 0.5% to 2.8%.
PETRA PÉTERFFY
The trick is figuring out how data centers, notorious power hogs, can keep operating when their flexible connections are throttled. Flexibility specialists envision three possible ways. The simplest is for the new data center to install on-site backup power storage or generation to tap when the grid is maxed out—at their own expense, of course.
A facility could also fill the gap by drawing on a VPP. The utility would turn down the electricity going to users who signed up for the VPP, and the data center would pay them for their flexibility. This method wouldn’t require any major infrastructure, but it would require the utility to have a big VPP program and to coordinate the exchange at a time when the grid was under stress. While VPPs exist to some extent in nearly 40 states, the rules governing them vary widely, and they are empowered to do more in some areas than in others.
Finally, a data center could simply use less power at peak times. The conventional wisdom is that they won’t go for such limits, particularly when every number-crunching server can feel like a goose potentially laying little golden eggs. But some experts are betting that the value of getting up and running quickly is enough to change their minds. “There is a clear and growing trend,” says Ayse Coskun, chief scientist at Emerald AI. “Operators are increasingly willing to trade some level of flexibility for faster grid interconnection.”
GridCare, a startup based in Silicon Valley, was one of the first companies to use flexibility to get data centers online quickly. Instead of looking at grids only in worst-case scenarios when electricity demand is highest, the company analyzes the system under all conditions, explains CEO Narayan, who studied smart grids at Stanford. It feeds every part of the grid—including power plants, lines, substations, and homes—into a generative AI model that creates a “digital twin” for different grid configurations. It then picks out results that could unlock capacity while maintaining reliability, and it feeds those into another model trained on the physics of electrical components like resistors and capacitors to make sure they’re realistic.
GridCare found its first customer in the Silicon Forest, an area in the Pacific Northwest named for the trees that dominate the landscape and the IT industry that has more recently sprouted up there. The local grid needed more capacity to support more data centers. “Data centers wanted ‘speed to power,’” says Isaac Barrow, a manager of data-center relations at Portland General Electric, or PGE, the local power generator and distributor, “but transmission buildout is a long process that’s very costly.”
In 2024, Aligned Data Centers came to PGE wanting to expand its operation in Hillsboro, Oregon, and PGE followed a recommendation from GridCare. Aligned will install a 31-megawatt battery, set to be in service in May 2027, and decrease its draw by up to that amount when the grid becomes congested. Bundled with other flexibility measures, that battery has allowed PGE to increase the capacity it can offer Aligned and other nearby operators by 80 megawatts without any new power plants. Though the buildout of data centers in Hillsboro has faced plenty of pushback from locals, Barrow points out that it could have the knock-on effect of lowering costs for ratepayers, because it spreads out the tab.
Other companies are promoting different flavors of flexibility. Google has been moving processing loads from facilities in areas experiencing demand spikes to those in less stressed spots since 2023. It’s signed agreements with five utilities, including the Tennessee Valley Authority and Indiana Michigan Power, that add as much as a gigawatt of flexibility.
Voltus, a major VPP provider across the US and Canada, markets a “bring your own capacity” program in which a data-center company can fund a VPP nearby. The grid operator can use the VPP to decrease demand at busy times, and participants get a financial thank-you. “We can spin up new VPPs on the order of months,” says Emily Orvis, Voltus’s vice president of energy markets. In June, the company signed their first such data-center deal: a three-year plan in which Google will bankroll a VPP in the PJM interconnection.
Of all the approaches to flexibility, Emerald AI’s may be the most ambitious: asking data centers to dial into the grid’s needs. The company’s Conductor software, which can run on premises or in the cloud, builds on the research of chief scientist Coskun. Her group at Boston University showed in a pair of 2013 papers that a data center could watch the grid and help balance big power fluctuations, such as the intermittent effects of solar and wind power. By 2022, she and her colleagues had tested their methods on a cluster of 36 research servers and shown that the system could respect power limits without breaking the processes it was running.
One of the most important questions for Conductor is deciding which AI processes can be slowed down to save energy without kneecapping performance. A lot of companies label their jobs by priority—a real-time chatbot query, for instance, might outrank something like a web search that’s part of a deep research project. When they don’t, Emerald AI tries to infer priority from the nature of the job. Conductor then analyzes the AI workload to determine how tweaking the power to a given processor will affect the performance and help meet the usage limits set by the grid operator.
“The performance curve changes for different kinds of workloads,” says Coskun. “Each AI job is going to have a different location on that curve. Our intelligence is figuring out where you are on that curve.”
PETRA PÉTERFFY
Last year, Emerald AI began assessing the technology’s readiness for real-world use in a series of tests, raising the difficulty each time. The trials were carried out in partnership with the Data Center Flexible Load Initiative—a collaboration among tech companies like Google and Nvidia, utilities like Duke Energy, and grid operators like PJM that aims to help establish a repeatable framework for power-flexible data centers.
The first challenge was in Phoenix, a fast-growing computing hub. For the test, Conductor took control of a group of server racks laden with 256 Nvidia A100 GPUs—hardware that can use about as much power as around 170 US homes. When presented with a simulation of a busy grid, Conductor reduced the power to the chips by 25% for three hours, while maintaining acceptable computing performance. Emerald AI and its partners reported the results in a paper in Nature Energy in December 2025.
The next trial forced the system to juggle surprise grid fluctuations without advance warning and redirect AI jobs from a data center in Virginia to a less busy one in Chicago. Then, in London, Conductor took the reins of equipment beyond the main GPU processors and faced a more complicated mix of fluctuations, including very short and long bouts of congestion—plus the notorious teakettle effect.
The progress so far shows that flexibility can work, at least in some situations, but only a small fraction of operators have pursued it as yet. “We’re just in the beginning innings of the game,” says Jesse Jenkins, one of the authors of the 2025 Princeton study and cofounder of Firma, a startup that works on data-center flexibility. “People are recognizing that this is a potential solution. The motivation is there; there are some bespoke examples. But there’s no uniform solution set that’s the default option, which is where we need to get.”
While data centers are going up across the US, no place on Earth comes close to the accumulated computing muscle in Northern Virginia’s Data Center Alley. The region is home to around 500 compute-crunching facilities, which represent 13% of the entire world’s capacity; the next two hot spots, Beijing and Oregon, contain 6% each.
There are proposals to build hundreds more facilities in Virginia, but a government study found that the state’s electricity demand will increase 183% (around 26 gigawatts) by 2040 if they all go forward, and supporting even half would be difficult. The power-flexible data center that Emerald AI, Nvidia, Digital Realty, and their partners are building in the suburb of Manassas could demonstrate how data centers can squeeze the power they need out of existing capacity. The facility, slated to come online later this year, is intended to give Conductor the chance to manage power at the largest scale yet and to respond to conditions on a live grid for the first time. In the UK demonstration, Conductor managed a 130-kilowatt AI cluster; in Manassas, it will pull the strings of a 96-megawatt hyperscale AI factory.
Some degree of flex will play a key role as we transition away from fossil fuels and toward a future that has to juggle technologies like solar and wind power, batteries, and electric cars.
For PJM, the Manassas facility points to a potential path through the current power crunch. “We think data-center flexibility, in different forms, will be essential for the reliable integration of data-center load over the short to mid term,” says Scott Baker, who manages demand-side markets at PJM.
But not all grid experts are so sanguine. PJM’s market monitor, which oversees the grid operator, says there are no workarounds when it comes to adding capacity. “The notion that large amounts of data-center load can be added without adding new generation is magical thinking,” says Joseph Bowring, an economist and the head of PJM’s market monitor since 1999.
One problem, he says, is that there’s no way to guarantee that a data center will actually take less power when demand is high. That is, absent any legal or regulatory push for flexibility or compliance, the utility won’t be able to step in to help prevent, say, a blackout. Utilities can rely on resources like power plants, but they can’t control or rely on data centers. “They do not want to be fully interruptible,” Bowring says of the facilities.
Stephen Empedocles, an advisor for technology companies, views flexibility as more of a tool than a silver bullet. “These approaches are excellent for improving grid reliability and getting more out of the infrastructure we already have,” he says, “but they are optimization tools.” They’re not substitutes for the “generation, transmission, and distribution expansion that will still be required,” he continues.
Flexibility advocates agree that over the long term, whether or not AI continues to boom, electrification will drive a need for more generation and transmission. Some degree of flex will play a key role in using grid infrastructure better as we transition away from fossil fuels and toward a future that has to juggle technologies like solar and wind power, batteries, and electric cars. A report published by the International Renewable Energy Agency in January 2026 found that grids around the world will need three times as much flexibility in 2030 as they had in 2019—and 10 times as much by 2050—to balance increasing demand with fluctuating supplies of renewable energy.
The challenge of powering AI could provide just the spark we need to do the work of designing and building smarter, more flexible grids, says Coskun. “I think with a crisis like this, there’s no quick solution,” she says. “Sometimes a crisis like this creates an opportunity to do something differently.”
Amos Zeeberg is a freelance science and technology journalist based in Bucharest. He’s developing a book about technology networks, including electric grids.
A decade since its founding, the International Human Cell Atlas Consortium is hosting a high-profile meeting in Boston this week, with panels featuring more than two dozen prominent academics and biotech industry leaders, including Genentech’s Aviv Regev, David Altshuler of Vertex Pharmaceuticals, and Eric Lander from the Broad Institute. The event, which is expected to draw hundreds of scientists from across the globe, comes at an inflection point in the HCA’s ambitious aim to build a comprehensive reference map of all the different types of cells that make up a human body.
Later this year, the HCA expects to deliver a first draft — the completion of single-cell atlases across all of the major organs and tissues — that promise to boost researchers’ understanding of how the body works. So far the HCA has focused on building a reference of healthy cells and the genes they express. In its next phase, it plans to tackle disease, and that means amassing knowledge about where particular cells are located, who their neighbors are, and who they’re communicating with — a rapidly emerging field known as spatial biology.
It’s embarking on this expansion when the field is awash in new technology options from companies like Vizgen, Bruker, Illumina, Takara Bio, Bio-Techne, and 10x Genomics, a Bay Area company whose single-cell RNA sequencing technology was the workhorse of the HCA’s first phase. Scientists who want to join this effort will be faced with decisions about which commercially available solutions to use.
Cancer drugs can shrink fast-growing tumors. But sometimes a few tumor cells survive. These “persister” cells seed new tumors, forcing cancer patients into arduous cycles of testing and treatment. The problem is that persister cells are rare—as few as one in a thousand tumor cells—and they’re genetically identical to the tumor, which makes them hard to find. Plus, their tenacity can be temporary, and by the time a scientist can get them in a petri dish, the qualities that helped them survive may have faded.
To figure out how to beat them, researchers at the University of California, San Francisco (UCSF), built a robotic system that treats thousands of mini tumors at once in the laboratory. Their resulting ResMap platform lets scientists systematically identify, track, and treat surviving cells. The platform revealed shared features among persister cells that could help explain why cancer comes back—features that could be exploited by future drug therapies to beat them. “A few years ago, people were still asking whether persister cells were real,” said Xiaoxiao “Vany” Sun, PhD, an assistant researcher in the UCSF Department of Pharmaceutical Chemistry. “Now we can find them and test ideas for how to eliminate them.”
Residual disease following targeted therapy remains a key challenge to achieving lasting responses in oncogene-driven cancers, the authors stated. Drug-tolerant persister cells, which the team describes as “subpopulations that survive initial therapy without stable genetic resistance,” can contribute to residual disease and seed tumor relapse. “Targeting drug-tolerant persister cells has emerged as an essential complement to oncogene-directed therapy, yet the field has lacked a unified framework to evaluate and prioritize candidate targets,” they wrote. “Understanding and targeting these cells have emerged as a promising strategy for achieving lasting therapeutic outcomes.”
Cancer cell persistence was first described in 2010, the authors explained, and studies have linked persister survival to different biological processes and resulted in “an expanding list” of candidate therapeutic targets. However, they noted, “… despite over a decade of research, no persister-directed therapy has reached clinical approval.”
For their reported study, the team gathered 94 drug candidates that other laboratories had flagged as potential persister therapies. They wanted to test each drug at different doses, on persisters from two types of lung cancer that had been treated with standard therapies. “As a testbed, we selected four lung cancer models: two with EGFR inhibitor osimertinib (EGFRi)–treated EGFRmut cell lines (PC9 and MGH134) and two with KRAS inhibitor sotorasib (KRASi)–treated KRASG12C cell lines (LU65 and MGH1138-1),” they wrote in summary. Each model was screened under normal oxygen and hypoxic conditions.
It would require 10,000 painstaking, week-long experiments—so they built a robotic platform to eliminate the labor and inconsistency of doing it by hand.
Thousands of miniature tumors sat in stacks of 384-well plates inside controlled incubators. A robotic arm, like those used in pharmaceutical drug screening, moved the plates between experimental stations. One station used sound waves to deposit tiny, precise doses of drug onto each tumor (first, a lung cancer therapy; then, an experimental persister therapy). Other stations stained the tumors with antibodies and took microscopic images of each tumor or group of persisters.
The overall ResMap platform incorporated multiple components, the team explained. “… we developed the ResMap platform incorporating four integrated components: an automated high-throughput workflow, machine learning-based normalization, a persistence-specific metric, and a validated framework.”
Their results showed that of the tested drugs, nine consistently weakened persister cells. The findings suggest that persister cells may share common vulnerabilities, even if they had emerged under different treatment conditions. “Initial screening identified 12 targets with conserved anti-persister activity across genotypes and oxygen environments; follow-up validation reproduced nine of these targets and revealed variable degrees of persister specificity relative to general cytotoxicity.” The investigators suggested that, “Collectively, these findings suggest that although persister biology involves multiple adaptive programs, targeting individual, well-chosen survival pathways may be sufficient to meaningfully reduce residual disease burden.”
Steve Altschuler, PhD, professor of pharmaceutical chemistry at UCSF and co-senior author of the paper, said, “We expected each tumor to behave as its own special case. Instead, we found patterns that held up across many different samples, suggesting there may be underlying rules that can help predict which therapies are most likely to work.”
The team plans to expand the platform to include more tumor types and treatment conditions. They hope the resulting dataset will be a resource to help researchers eliminate persister cells before they can give rise to drug-resistant disease. “ResMap provides a community resource for coordinated validation efforts and rational combination design aimed at minimizing residual disease following anticancer therapy,” they stated.
With over a decade of hands-on experience in the biopharmaceutical industry, Victoria specializes in the design and implementation of ready-to-use solutions and single-use consumables supporting downstream purification processes. She brings a strategic, highly collaborative approach to problem-solving, partnering closely with cross-functional teams to deliver scalable improvements that enhance operational efficiency and drive successful results.
Victoria is passionate about building strong team environments, supporting diverse learning styles, and applying data-driven decision-making to optimize performance across the process lifecycle.
Cole Cordes
Head of Manufacturing, Supply Chain and MSAT Bionova Scientific
Panelist
Cole Cordes
With more than 30 years of leadership experience in the biopharmaceutical and life sciences industries, Cole specializes in manufacturing operations, supply chain strategy, and MSAT across the product lifecycle. He brings a strategic, results-driven approach to operational excellence, partnering with cross-functional teams to optimize manufacturing performance, strengthen supply reliability, and support successful commercialization.
Cole is passionate about building high-performing organizations, developing talent, and leveraging data-driven decision-making to drive continuous improvement, scalability, and business growth.
Broadcast Date:
Time:
Downstream bottlenecks often stem from early process design decisions that fail to fully account for scale, variability, and the manufacturing realities of therapeutic modalities such as monoclonal antibodies.
As upstream titers rise and novel modalities introduce added complexity, these early oversights can force reactive workarounds that impact throughput, cost, and product quality. By taking a more deliberate and forward-looking approach, teams can reduce downstream risk and build processes that are better equipped for manufacturing scale.
In this GEN webinar, our speakers will examine five common planning gaps that can contribute to bottlenecks, including single-source material dependency, raw material pack size selection, sensitive buffer designs, and single-use systems designed without realistic failure modes. Using real-world MSAT and tech transfer examples, they will illustrate how, when overlooked, these drivers can lead to deviations, safety risks, and longer cycle times—and how to proactively address them. The webinar explores practical strategies that can help evaluate materials, buffer systems, and consumables through a scale‑ready lens—helping teams build more robust purification processes and avoid these common bottlenecks.
A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.
Officials at Leiden, Netherlands-based CRO ZoBio say the company has launched a DNA-Encoded Library (DEL) discovery service, which is designed to help biotech and pharmaceutical companies generate validated, progressible hits against novel and challenging drug targets.
The new offering combines structure-grade protein production, quantitative biophysics, DEL screening, off-DNA hit validation and X-ray crystallography into a single workflow, according to a company spokesperson, who explains that it enables clients to move beyond hit identification toward high-confidence starting points for drug discovery programs.
ZoBio maintains that unlike transactional DEL screening approaches that focus solely on hit generation, its platform is designed to deliver biologically relevant, structurally characterized hit matter with clear potential for progression. The service is particularly suited to exploratory and difficult-to-drug targets, including protein–protein interactions (PPIs) and targets with poorly defined binding pockets, where conventional screening approaches often fail, notes Gregg Siegal, CEO of ZoBio.
“Drug discovery teams today are increasingly focused on highly validated but technically challenging targets, where traditional screening approaches can struggle to deliver meaningful starting points,” he continues. “Our approach combines DEL technology with the structural biology, biophysics, and assay expertise needed to generate hits that clients can confidently progress.”
Siegal also points out that the DEL service is library-agnostic, enabling clients to access commercially available DEL collections or apply ZoBio’s workflow to proprietary client-owned libraries. The integrated platform reportedly includes:
Structure-grade protein production and characterization
Quantitative biophysical assay development using techniques such as SPR
Biophysically informed DEL selection design
Interactive DEL data analysis and hit prioritization
Off-DNA hit resynthesis and orthogonal validation
Structural characterization through X-ray crystallography
Mechanistic insight to support downstream optimization
The workflow is designed to support collaborative decision-making throughout the discovery process, helping clients rapidly establish whether difficult or exploratory targets are viable for further development, according to Siegal, who says that members of the ZoBio team will be available for meetings during the BIO International Convention in San Diego to discuss the new service.
Flu shots reduce hospitalizations and deaths for the roughly one billion people worldwide that get the flu each year. But they are less effective when the vaccine strains don’t closely match the viruses circulating in the community. Today’s vaccines are made months in advance of the flu season due to a long manufacturing process. When projections are off, strain mismatch can reduce the efficacy of the flu vaccines from about 60% (in a good year) down to 19%. A broader immune response could translate to a more effective vaccine even when the virus is changing faster than vaccine makers can update their shots.
Now, an investigational mRNA influenza vaccine, developed by Moderna, helps the immune system recognize a wider range of influenza viruses than today’s standard flu shot, offering stronger and potentially longer-lasting protection. The vaccine is currently under review by the U.S. Food and Drug Administration and, if approved, would be the first mRNA vaccine against influenza.
“We are seeing that the mRNA flu vaccine doesn’t just boost the immune system’s response to what it has already seen, it can help expand and diversify the antibody response, covering a broader range of flu strains,” said Ali Ellebedy, PhD, professor in the department of pathology and immunology at WashU Medicine. “If we can make flu immunity broader and more durable, that could mean fewer hospitalizations and deaths, which translates into a major impact on public health.”
In a separate Phase III clinical trial, Moderna found that its mRNA-based flu vaccine reduced the risk of illness by 26.6% more than the standard flu vaccine in older adults. Seeking to understand possible causes of this improved protection, the new study examined how immune responses to the mRNA-based flu vaccine differ from those of the standard vaccine.
The researchers followed 75 adults ages 20 to 50 over either the 2022-2023 flu season or the 2023-2024 flu season. About half received the investigational mRNA vaccine (mRNA-1010). The other half got Fluarix, an approved flu shot containing inactivated influenza viruses. Both vaccine platforms targeted the same strains recommended by the World Health Organization for the two flu seasons.
Analyzing blood samples, the researchers found a stronger immune response in participants who received the mRNA vaccine compared with participants who received the standard flu shot. Specifically, those given the mRNA vaccine produced more flu-specific antibodies and more flu-specific memory B cells.
“Influenza is constantly evolving to evade our immune system,” said Hanover Matz, PhD, a postdoctoral research associate working in Ellebedy’s laboratory. “But if we can develop vaccines that activate diverse B cells that target a broad portfolio of flu viruses, we have a better chance of avoiding strain mismatches and potentially even reducing the frequency with which the vaccine is needed.”
To investigate the vaccine’s ability to diversify B cells, the researchers studied germinal centers—where B cells improve their ability to recognize the virus and generate slightly different versions of themselves—in a subset of participants. It had not been previously understood if mRNA-based influenza virus vaccines can induce a superior germinal center (GC) response.
Among 13 people receiving the mRNA flu vaccine, five developed flu-specific germinal center responses in the lymph nodes that persisted for the 26 weeks of the study. In contrast, persistent immune responses were not seen in the 15 participants who received the traditional flu shot.
In addition, from four weeks after vaccination until the six-month mark, antibodies from mRNA vaccine recipients recognized and bound to many diverse flu strains across many decades of viral evolution, especially those known to cause the most widespread illness. Antibodies from standard vaccine recipients bound to fewer divergent virus strains.
These findings, the authors note, reveal a key role for persistent GC responses in broadening the repertoire of vaccine-induced antibodies. “We are seeing that the mRNA flu vaccine is driving strong, persistent germinal center responses,” said Ellebedy. “This can broaden the antibody response and better arm the immune system against an ever-changing virus.”
In a study published in Cell titled, “Deep learning of functional perturbations from condensate morphology,” researchers at Princeton University have applied AI to understand how drugs affect the dynamics of key structures within the cell. The work introduces a tool that can map morphology to functional outcomes and shed light on markers of health.
The authors examined the changes in shape of biomolecular condensates, tiny droplets in cells that drive transcription and other gene regulation processes linked to disease, including Alzheimer’s, ALS and cancer. The findings support a robust system for monitoring and evaluating cellular responses to drugs at a single-cell level.
“The central problem in biology is how do you get emergent structure from individual molecular interactions,” said Cliff Brangwynne, PhD, professor of chemical and biological engineering at Princeton and corresponding author of the study. “The key innovation here was to develop a way to learn from the images and classify the patterns that are emergent.”
The team used an advanced microscope to image nucleolar morphology changes in hundreds of human cells under a range of drug-controlled conditions. Machine learning tools sorted the images into four basic categories based on the shape of the nucleolus, uncovering “cap” and “necklace” shapes linked to cellular stress responses.
The authors ran a panel of drugs to examine the effect on nucleolar formation and measured changes in the condensate’s development. Varying concentrations caused different degrees of change in both caps and necklaces.
Two known anti-cancer drugs caused caps, while a third drug, called topotecan, triggered a new nucleolus morphology that the researchers labeled “flower.” While topotecan inhibits TOP1, an key enzyme during DNA replication, loss of TOP1 induced the flower shape and uncovered the enzyme’s role in maintaining nucleolar organization by regulating RNA processing.
“No one’s seen this flower morphology before,” said Brangwynne. “The network flagged it as not fitting neatly into the other three categories.”
The team also tested their neural network on other condensates related to RNA processes, observing similar dose-and-response results for drugs specific to nuclear speckles, a hub for messenger RNA activity, and condensates from respiratory syncytial virus.
This finding underscores the value of analyzing morphological changes. “You could be missing other important features,” said Anita Donlic, PhD, postdoctoral researcher and first author of the study. “Things that could tell you there’s new biology.”
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
A worsening shortage of Bicillin, Pfizer’s injectable form of penicillin, left an Arizona woman unable to receive timely treatment for syphilis during pregnancy.
Also, the FDA approved Sanofi’s diabetes drug Tzield after an unusually contentious review process, and the Trump administration has proposed closing a Medicare negotiation loophole.
